This study characterized clinical factors predictive of cardiogenic shock developing after thrombolytic therapy for acute myocardial infarction (AMI).
Cardiogenic shock remains a relatively common complication of acute myocardial infarction (AMI), still portending an ominous prognosis despite the advent of new or refined therapeutic strategies (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . By identifying patients at risk for developing cardiogenic shock, preventive measures may be implemented in an attempt to avert the development of shock. The aim of the current study was to develop a model to predict the occurrence of cardiogenic shock among patients with AMI receiving thrombolytic therapy in the Global Utilization of Streptokinase and TissuePlasminogen Activator for Occluded Coronary Arteries-I (GUSTO-I) trial (19) and to validate it in another large cohort of patients receiving thrombolytic therapy for AMI.
METHODS
The details and results of the GUSTO-I trial have been previously reported (19) . In brief, 41,021 patients from 15 countries presenting within 6 h of the onset of chest pain with typical electrocardiographic (ECG) changes (Ͼ0.1 mV ST-segment elevation in Ն2 limb leads or Ͼ0.2 mV in Ն2 precordial leads) were eligible for randomization to one of four intravenous (IV) thrombolytic strategies: 1) streptoki-nase (Kabikinase, Kabi Vitrum, Stockholm, Sweden), 1.5 million U over 1 h, with subcutaneous heparin; 2) streptokinase with IV heparin; 3) accelerated recombinant tissuetype plasminogen activator (Activase, Genentech, South San Francisco, California), 15 mg bolus followed by infusion at 0.75 mg/kg (Յ50 mg) for 30 min and 0.5 mg/kg (Յ35 mg) over the next hour, and IV heparin; 4) tissue-type plasminogen activator (1.0 mg/kg over 1 h (Յ90 mg)) and streptokinase (1 million U over 1 h) with IV heparin. Adjunctive therapy included chewable aspirin (Ն160 mg; Bayer) followed by 160 to 325 mg/day, and IV atenolol (10 mg; ICI Pharmaceuticals, Wilmington, Delaware) followed by daily oral therapy (50 to 100 mg).
Other medications were given at the discretion of the attending physician. Angiography, right-heart catheterization, percutaneous coronary revascularization, intraaortic balloon pumping and coronary bypass surgery were also used at the discretion of the attending physician.
Patients with cardiogenic shock were prospectively identified (5, 15, 16, 18) . Cardiogenic shock was defined as systolic blood pressure Ͻ90 mm Hg for Ն1 h that was not responsive to fluid administration alone, thought to be secondary to cardiac dysfunction, and associated with signs of hypoperfusion or cardiac index Յ2.2 liters/min/mm 2 and pulmonary capillary wedge pressure Ͼ18 mm Hg. Patients in whom systolic blood pressure increased to Ͼ90 mm Hg within 1 h after administration of positive inotropic agents, or patients who died within 1 h of hypotension but met other criteria for cardiogenic shock, were still classified as having cardiogenic shock. In the current analysis we excluded patients who presented with shock or who were missing precise data as to the timing of shock relative to the time of enrollment. To characterize the temporal relationship of shock to thrombolytic therapy, the occurrence of shock was also analyzed based on its timing after enrollment: Յ1 h, Ͼ1 to 2 h, Ͼ2 to 6 h, Ͼ6 to 24 h, Ͼ24 to 48 h, and Ͼ48 h.
Statistical analysis.
Continuous variables are presented as medians with 25th and 75th percentiles and discrete variables as frequencies and percentages. Multivariable Cox proportional hazards survival modeling techniques were used to develop a model to predict the time to in-hospital cardiogenic shock. Missing characteristics were imputed for all patients with partial data using a method for simultaneous imputation and transformation of predictor variables based on the concepts of maximum generalized variance and canonical variables (20) . A backward-elimination method was used to determine the significant predictors in the model (elimination criterion, p Ͼ 0.05). Because the precise timing was not available for invasive procedures such as angioplasty or intraaortic balloon counterpulsation, we did not include these variables in our analyses. Predictors in the above models were tested using the Wald chi-square test. Results are also presented as hazard ratios and 95% confidence intervals (CI). Once the final model was developed, bootstrapping was used (21, 22) for internal validation (100 bootstrapping samples). The quality of the final model based on the original as well as the bootstrapped samples is described with the use of the concordance index, which is a description of the discriminant power of the model to reliably predict an outcome (23) .
On the basis of the coefficients in the model, a probability chart was developed for the occurrence of shock in-hospital. As we previously described (18) , each variable in the model received a certain score based on the value of the variable. The total points were then transformed into predictive values.
Validation. For verification purposes, the model we developed in the GUSTO-I cohort was used in the Global Use of Strategies to Open Occluded Coronary Arteries III (GUSTO-III) cohort (24) . In GUSTO-III, 30-day outcome of patients randomized to receive either reteplase or alteplase was equivalent. We have previously reported that treatment with alteplase versus reteplase did not have an effect on the occurrence or the outcome of shock in GUSTO-III (25) .
Of the 15,058 patients enrolled in GUSTO-III, we eliminated 83 from this analysis because they presented with shock and an additional 15 because we were unable to determine from available data when they developed shock; this left a modeling sample of 14,960 patients. We tested the GUSTO-I shock model in this GUSTO-III population, of whom 643 patients developed cardiogenic shock after enrollment.
RESULTS
Patient population. Of the 41,021 patients enrolled in the GUSTO-I trial, data regarding shock status were missing for 305. Of the remaining 40,716 patients, 680 were excluded because they developed shock prior to enrollment, and 383 were excluded because they had severe hemodynamic compromise after enrollment but did not meet our strict criteria for shock. This analysis pertains to the 1,889 patients who unequivocally developed shock after admission.
Time to shock. The median time from enrollment to shock was 11.6 (2.2, 41.9) h. Shock developed within 6 h of enrollment in 39.6% of shock patients and within 24 h in Baseline characteristics. In general, the patients who developed shock after enrollment were older than nonshock patients and were more commonly women. The shock patients also had more co-morbid conditions such as hypertension and diabetes mellitus, but they were less frequently cigarette smokers. More shock patients had experienced a prior infarction. The physical examination revealed that more shock patients arrived with Killip classes II and III and that upon presentation their systemic blood pressure was lower and their heart rate higher. There were several differences in baseline characteristics among the various shock groups categorized based on the timing of shock (Table 1) . Shock developed earlier in younger patients who were more commonly cigarette smokers and more frequently had inferior wall AMI. The patients with early shock had lower blood pressure upon presentation without a significant difference in heart rate or Killip class. The relationship between age, weight, and diastolic blood pressure and developing shock was linear. The relationship between the systolic blood pressure and heart rate and developing shock was more complex, as is evident in Figures  1 and 2 , respectively.
Model. In the Cox proportional hazards survival model (

Algorithm.
We converted the results of the model into a scoring system algorithm (Table 3) . Based on certain categorical clinical features such as prior AMI or gender, as well as the value of continuous variables such as age or systolic blood pressure upon presentation, a composite score can be calculated. This composite score can then be used to estimate the risk of developing shock after thrombolytic therapy. 
Validation. The same four variables as in the GUSTO
DISCUSSION
Current therapeutic approaches to cardiogenic shock remain of limited efficacy. Even using aggressive revascularization interventions, short-term mortality has reached Ͼ70% in recent series of shock patients (8, 17) . In the absence of overwhelmingly effective treatments for shock, an alternative approach is to identify patients at high risk for developing shock and to attempt to avert its development. In the present study we identified 1,889 patients who developed cardiogenic shock after they were enrolled and who were randomized to various thrombolytic therapies in the GUSTO-I trial. Using this population, we developed a model to predict the occurrence of shock. To validate it, we applied it to the GUSTO-III patient population.
Predictors of shock.
Our findings demonstrate that certain demographic and clinical parameters are strongly associated with the development of shock after thrombolytic therapy. Older age was the variable most strongly associated with the occurrence of shock: for every 10-year increase in age, the Table 1. CI ϭ confidence interval; BP ϭ blood pressure; MI ϭ myocardial infarction; PTCA ϭ percutaneous transluminal coronary angioplasty; CABG ϭ coronary artery bypass grafting surgery; tPA ϭ tissue-plasminogen activator; SK ϭ streptokinase; IV ϭ intravenous; Combo ϭ combination of tissue-plasminogen activator and streptokinase; SQ ϭ subcutaneous.
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Predictors of Shock After Thrombolysis for AMI risk of developing shock was greater by 47%. In addition, simple parameters derived from the physical examination, such as systolic blood pressure, heart rate and Killip class among patients who did not present with shock, were strong predictors of shock developing subsequently. Together, the patient's age and these physical parameters provided Ͼ85% of the information needed to predict shock in our model. These variables have also been shown to be major predictors of 30-day mortality in an analysis of the entire GUSTO-I cohort (26) .
Comparison with prior studies. Leor et al. (27) previously reported that in the prethrombolysis era, among patients Figure 1 . The relationship between systolic blood pressure (BP) upon presentation and the probability of shock developing after thrombolytic therapy. Figure 2 . The relationship between heart rate upon presentation and the probability of shock developing after thrombolytic therapy. 20  6  40  3  80  59  40  4  30  12  60  0  100  49  60  5  40  19  80  8  120  39  80  7  50  25  100  14  140  32  100  9  60  31  120  17  160  27  120  11  70  37  140  19  180  23  140  13  80  43  160  22  200  18  160  15 In panel 1, find the value most closely matching the patient's risk factors and circle the points. In panel 2, sum the points for all predictive factors. In panel 3, determine the predicted occurrence of cardiogenic shock corresponding to the total number of points. For example, a 71-year-old 60-kg female from the U.S. with a history of hypertension, who presents with a systolic blood pressure of 126 mm Hg, a diastolic blood pressure of 64 mm Hg, a heart rate of 123 beats/min, in Killip class III, and an anterior myocardial infarction who was then treated with intravenous streptokinase, would have a total score of (37ϩ17ϩ39ϩ5ϩ10ϩ5ϩ8ϩ17ϩ[3ϩ2ϩ5]) ϭ 148. This score corresponds to predicted probability of 30% for cardiogenic shock occurring after thrombolytic therapy. BP ϭ blood pressure; MI ϭ myocardial infarction; Tx ϭ thrombolytic therapy; PTCA ϭ percutaneous transluminal coronary angioplasty; CABG ϭ coronary artery bypass grafting surgery; tPA ϭ tissue-plasminogen activator; SK ϭ streptokinase; IV ϭ intravenous; Combo ϭ combination of tissue-plasminogen activator and streptokinase; SQ ϭ subcutaneous; US ϭ patients enrolled in the U.S.; Wght ϭ weight.
with AMI without clinical signs of heart failure upon presentation, cardiogenic shock developed in-hospital in 89 (2.6%) of 3,465 patients. Among the independent predictors for in-hospital shock were older age, female sex, prior angina, prior stroke and peripheral vascular disease. Hands et al. (28) reported that shock developed in 60 (7.1%) of 845 patients admitted with AMI also in the prethrombolysis era. Independent predictors of the occurrence of shock were age Ͼ65 years, left ventricular ejection fraction Ͻ35%, larger infarct as estimated by serial enzyme determinations, prior AMI and diabetes mellitus. In these earlier studies (27, 28) , parameters from the physical examination were not included in the analysis.
Our study of 1,889 patients who developed shock after thrombolytic therapy complements these prior studies, demonstrating again the strong association between increased age and the occurrence of shock. Moreover, our study underscores the importance of the physical examination; variables easily derived from the physical examination were of much greater significance in predicting the occurrence of shock than other variables such as prior AMI or infarct location. Similarly, we have recently demonstrated that other variables derived from the physical examination such as altered sensorium, oliguria and cold, clammy skin were of great significance in predicting death among patients with shock (18) .
Timing of shock. The challenge for the clinician is to promptly and thoroughly identify the patient at risk for developing shock and to avert this complication. In the prethrombolysis era, Leor et al. (27) reported that shock developed at a mean of 4 Ϯ 4 days after admission (median two days, range 3 h to 16 days) in patients who were admitted with Killip class I, and Hands et al. (28) reported that shock occurred at a mean of 3.4 Ϯ 0.8 days (with half the patients developing shock within the first 24 h) in patients who did not have shock upon admission. More recent data have stressed the earlier occurrence of shock (7, 12) ; shock occurred at a median of 9 h after onset of AMI. In GUSTO-I, we observed that among patients who did not present with shock and who received thrombolytic therapy, shock developed at a median of 11.6 h. Moreover, shock developed within 6 h in 39.6% of shock patients and within 24 h in 63.2% of such patients. These data indicate that the window of opportunity to attempt to avert the development of shock is very short-lived; patients must be identified and measures should be taken within hours of presentation.
Study limitations.
There are several caveats to consider in interpreting our results. First, our analysis pertains only to patients who did not die or develop shock before arrival at the hospital and who were well enough to sign a written informed consent to participate in a randomized trial. Moreover, this cohort included only patients with STsegment elevation upon presentation who were eligible for thrombolytic therapy. Second, some of the patients who came in with a low blood pressure may have been in subclinical shock. However, the study protocol also required that the hypotension be accompanied by signs of hypoperfusion to define shock. Apparently the attending physicians did not consider these patients to be in cardiogenic shock using our definition.
Third, in the current study we identified patients at risk of developing shock but did not prove that it is possible to avert the occurrence of shock after thrombolytic therapy. Although thrombolytic therapy in itself has reduced the occurrence of shock (29, 30) , there is no evidence as yet that other measures after thrombolytic therapy influence the development of shock. However, revascularization after thrombolytic therapy may be of value in high-risk populations, in contrast to its lack of effect when applied indiscriminately (31, 32) . Unfortunately, in current clinical practice, revascularization is more commonly offered to lowerrisk patients (33) (34) (35) .
In addition, the administration of therapeutic agents that improve cardiac myocyte metabolism, such as IV glucoseinsulin-potassium solutions (36) , may prove to be salutary. Studies investigating the efficacy of aggressive revascularization or other measures after thrombolytic therapy in preventing shock in high-risk subpopulations, such as those identified by our model, are warranted.
Conclusions.
We devised a simple scoring system to predict the risk of cardiogenic shock occurring after thrombolytic therapy, and we validated it in an independent cohort. Based primarily on the age of the patient and findings easily derived from the physical examination upon presentation, it is possible to estimate with accuracy the risk of shock. The physician attending to the patient with AMI now faces the challenge of promptly identifying the patient at risk and taking measures to avert the occurrence of shock.
